A detailed history of Rubric Capital Management LP transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Rubric Capital Management LP holds 26,713,503 shares of HRTX stock, worth $42.7 Million. This represents 1.48% of its overall portfolio holdings.

Number of Shares
26,713,503
Previous 26,713,503 -0.0%
Holding current value
$42.7 Million
Previous $93.5 Million 43.14%
% of portfolio
1.48%
Previous 2.77%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023

BUY
$0.97 - $1.8 $14.5 Million - $26.9 Million
14,963,503 Added 127.35%
26,713,503 $27.5 Million
Q4 2022

Feb 10, 2023

BUY
$2.25 - $4.67 $20.8 Million - $43.1 Million
9,233,672 Added 366.95%
11,750,000 $29.4 Million
Q3 2022

Nov 14, 2022

BUY
$2.66 - $5.37 $6.69 Million - $13.5 Million
2,516,328 New
2,516,328 $10.6 Million
Q2 2019

Aug 13, 2019

SELL
$16.93 - $26.22 $25.4 Million - $39.3 Million
-1,500,000 Closed
0 $0
Q1 2019

May 10, 2019

SELL
$23.15 - $28.34 $29.8 Million - $36.5 Million
-1,287,592 Reduced 46.19%
1,500,000 $36.7 Million
Q4 2018

Feb 13, 2019

BUY
$22.03 - $32.01 $18.3 Million - $26.5 Million
828,742 Added 42.31%
2,787,592 $72.3 Million
Q3 2018

Nov 13, 2018

BUY
$30.0 - $40.85 $24.6 Million - $33.4 Million
818,603 Added 71.79%
1,958,850 $62 Million
Q2 2018

Aug 14, 2018

SELL
$26.4 - $42.0 $9.76 Million - $15.5 Million
-369,761 Reduced 24.49%
1,140,247 $44.3 Million
Q1 2018

May 14, 2018

SELL
$18.43 - $28.8 $12.7 Million - $19.8 Million
-687,304 Reduced 31.28%
1,510,008 $41.7 Million
Q4 2017

Feb 14, 2018

BUY
$14.8 - $18.85 $4.4 Million - $5.6 Million
297,312 Added 15.65%
2,197,312 $39.8 Million
Q3 2017

Nov 13, 2017

BUY
$14.65 - $16.85 $27.8 Million - $32 Million
1,900,000
1,900,000 $30.7 Million

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $190M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Rubric Capital Management LP Portfolio

Follow Rubric Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rubric Capital Management LP with notifications on news.